KEGG   DRUG: Insulin glargine and lixisenatide
Entry
D11034            Mixture   Drug                                   

Name
Insulin glargine and lixisenatide;
Insulin glargine (genetical recombination) and lixisenatide;
Soliqua (TN)
Product
Component
Insulin glargine [DR:D03250], Lixisenatide [DR:D09729]
Remark
Therapeutic category: 3969
ATC code: A10AE54
Product: D11034<JP/US>
Efficacy
Antidiabetic
  Disease
Type 2 diabetes mellitus [DS:H00409]
Target
INSR (CD220) [HSA:3643] [KO:K04527]
GLP1R [HSA:2740] [KO:K04581]
  Pathway
hsa04910  Insulin signaling pathway
hsa04911  Insulin secretion
hsa04930  Type II diabetes mellitus
hsa04931  Insulin resistance
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 A ALIMENTARY TRACT AND METABOLISM
  A10 DRUGS USED IN DIABETES
   A10A INSULINS AND ANALOGUES
    A10AE Insulins and analogues for injection, long-acting
     A10AE54 Insulin glargin and lixisenatide
      D11034  Insulin glargine and lixisenatide <JP/US>
USP drug classification [BR:br08302]
 Blood Glucose Regulators
  Antidiabetic Combinations
   Insulin Glargine/ Lixisenatide
    D11034  Insulin glargine and lixisenatide
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   396  Antidiabetic agents
    3969  Others
     D11034  Insulin glargine and lixisenatide
Target-based classification of drugs [BR:br08310]
 G Protein-coupled receptors
  Secretin receptor family
   Glucagon
    GLP1R
     D11034  Insulin glargine and lixisenatide <JP/US>
 Protein kinases
  Receptor tyrosine kinases (RTK)
   INSR family
    INSR (CD220)
     D11034  Insulin glargine and lixisenatide <JP/US>
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11034
Other DBs
PubChem: 350078353
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system